The Case of Dolutegravir Plus Darunavir Antiretroviral Regimens: Is It Always Useful to Double the Drug Doses?
Dolutegravir trough concentrations were significantly reduced in PWH receiving darunavir/ritonavir twice daily. This evidence should be carefully considered in clinical conditions requiring higher dolutegravir exposure, such as in the presence of drug-drug interactions with drugs known to reduce dolutegravir bioavailability or in highly experienced PWH.
Authors
- Spinello Antinori (ORCID: https://orcid.org/0000-0003-0569-9407)
- Andrea Giacomelli (ORCID: https://orcid.org/0000-0003-3685-4289)
- Alberto Dolci (ORCID: https://orcid.org/0000-0002-9833-7538)
- Antonella Castagna (ORCID: https://orcid.org/0000-0002-8338-9714)
- Anna Lisa Ridolfo (ORCID: https://orcid.org/0000-0003-1106-6219)
- Dario Cattaneo (ORCID: https://orcid.org/0000-0003-1512-6530)
- Cristina Gervasoni (ORCID: https://orcid.org/0000-0002-4922-6495)
Institutions
- Vita-Salute San Raffaele University (IT)
- University of Milan (IT)
- ASST Fatebenefratelli Sacco (IT)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1097/ftd.0000000000001259
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39